Atara Biotherapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. My name is Pascal Touchon, the CEO of Atara Biotherapeutics. Pleasure to be here, and thank you, JP Morgan, for inviting us to present today.
After the usual forward-looking statement, I'd like to really spend the next few minutes in telling why Atara is in the unique position in the allogeneic cell therapy field, not only with the fact that we are the first ever to have delivered on the transformative potential of allogeneic cell therapy with the approval of Ebvallo in Europe in December of 2022. This is the first even still the only allogenic T cell therapy approved in the world, in that case, for the treatment of post-transplant lymphoproliferative disorder.
So very exciting milestone that we achieved some months ago, and now we are busy putting together the BLA submission for the US FDA that we expect to file in Q2 of this year. And that's very exciting because we can then bring tab-cel, Ebvallo in Europe to American patients, on top of having brought that to European
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
